---
title: "NXGL: Q2 2026 revenue up 27.8% to $3.7M, but net loss widened and going concern risks persist"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296088966.md"
description: "Q2 2026 revenue rose 27.8% year-over-year to $3.7M, driven by new biomaterial product sales, but gross margin fell to 30.1% and net loss widened to $3.6M. The company completed a major asset acquisition, raised $8.6M in convertible notes, and faces going concern risks due to recurring losses and negative working capital.Original document: NexGel, Inc [NXGL] SEC 10-Q Quarterly Report — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-17T10:06:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296088966.md)
  - [en](https://longbridge.com/en/news/296088966.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296088966.md)
generator: "portal-rs"
---

# NXGL: Q2 2026 revenue up 27.8% to $3.7M, but net loss widened and going concern risks persist

Q2 2026 revenue rose 27.8% year-over-year to $3.7M, driven by new biomaterial product sales, but gross margin fell to 30.1% and net loss widened to $3.6M. The company completed a major asset acquisition, raised $8.6M in convertible notes, and faces going concern risks due to recurring losses and negative working capital.

Original document: NexGel, Inc \[NXGL\] SEC 10-Q Quarterly Report — Aug. 25 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [NXGL.US](https://longbridge.com/en/quote/NXGL.US.md)
- [NXGLW.US](https://longbridge.com/en/quote/NXGLW.US.md)

## Related News & Research

- [AGAT: H1 2026/27 profit declined, but revenue rose and a major shopping center acquisition is underway](https://longbridge.com/en/news/297473748.md)
- [07:27 ETPartsSource Names Nick Marzotto to Lead Artificial Intelligence Strategy](https://longbridge.com/en/news/297644065.md)
- [CYTK: Aficamten showed robust efficacy and manageable safety in non-obstructive HCM, with FDA submission planned](https://longbridge.com/en/news/297306529.md)
- [BARRA: Net loss halved and biological risks reduced, but revenue declined amid ongoing strategic transformation](https://longbridge.com/en/news/297340993.md)
- [TXT: Q1 2026/27 saw robust MRR growth and record future revenues, despite lower margins](https://longbridge.com/en/news/297350031.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**